May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone synthase inhibitor (ASI) for treating hypertension in combination with other ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
-
-
Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American College of Cardiology’s Annual Scientific Session (ACC.26) that took place in March ...
-
April 23, 2026 — A new study analyzing data from more than 13,000 patients found that people using the increasingly popular weight-loss drugs known as GLP-1 receptor agonists (GLP-1-RAs) have a ...
-
Aug. 07, 2025 —- New research by European cybersecurity company Modat revealed more than 1.2 million internet-connected healthcare devices and systems are exposed and vulnerable to exploitation ...
July 16, 2025 — Insmed Inc. recently announced positive 12-Month data from the ongoing open-label extension (OLE) study ...
July 20, 2026
July 16, 2026 — Merck has received U.S. Food and Drug Administration (FDA) approval for Lipfendra (enlicitide) tablets ...
July 16, 2026
July 14, 2026 — Atrium Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its ...
July 14, 2026
May 18, 2026 — AstraZeneca’s Baxfendy (baxdrostat) has been approved in the U.S. as a first-in-class aldosterone ...
May 18, 2026
Feature | Heart Failure | Kyle Hardner
Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...
May 13, 2026
April 23, 2026 — A new study analyzing data from more than 13,000 patients found that people using the increasingly ...
April 23, 2026
Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...
January 28, 2026
Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...
November 19, 2025
Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...
September 25, 2025
Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...
September 23, 2025
Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...
September 05, 2025
Aug. 07, 2025 —- New research by European cybersecurity company Modat revealed more than 1.2 million internet-connected ...
August 08, 2025
July 25, 2025 — Data in recent staffing surveys from the American Society of Radiologic Technologists show that vacancy ...
July 25, 2025
The American Heart Association recently announced that Dr. Christine E. Seidman, an internationally renowned physician ...
May 02, 2025
July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...
July 10, 2024